Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sitmutolimod
- Development stage
- Phase 1
- Lead developer
- Parr Biotechnology
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
Sitmutolimod (formerly known as HP007) is an investigational synthetic C-type CpG oligodeoxynucleotide (CpG ODN) that acts as a Toll-like receptor 9 (TLR9) agonist. Developed by Parr Biotechnology (formerly Huapu Biotechnology), sitmutolimod is designed to stimulate the innate immune system, particularly activating plasmacytoid dendritic cells (pDCs), natural killer (NK) cells, and CD8+ T cells to promote a robust Th1-biased immune response and elicit antineoplastic activity. It is being evaluated as an intratumoral monotherapy in Phase 1 clinical trials for relapsed or refractory advanced solid tumors. Additionally, sitmutolimod is a key component of SV-102, an intratumorally administered fixed-dose combination therapy developed by Syncromune (as part of their SYNC-T platform) that also includes abazistobart (anti-PD-1), futermestotug (anti-CTLA-4), and ciltistotug (CD40 agonist) for the treatment of metastatic prostate cancer.
- Other names
- sitmutolimodum
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on sitmutolimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sitmutolimod.